Accessibility Menu
BIO-key International logo

BIO-key International(NASDAQ) BKYI

Current Price$39.16
Market Cap$316.13MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1997)-100%
5 Year+218%
1 Year+100%
1 Month-1%
BIO-key International last closing stock price
MetricPriceDate
Last closeUSD 38.182026-07-23
BIO-key International stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-10.79%USD 42.802026-07-16
1 month-0.91%USD 38.532026-06-23
3 month+44.68%USD 26.392026-04-24
Year to date+31.11%USD 29.122025-12-31
1 year+100.31%USD 19.062025-07-23
3 year+244.27%USD 11.092023-07-24
5 year+218.17%USD 12.002021-07-23
Since inception-100%USD 133,919.931997-02-24

BIO-key International Financials at a Glance

Market Cap

$316.13MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$6.63M

Net Income (TTM)

-$4.02M

EPS (TTM)

$1.16

P/E Ratio

32.81

Dividend

$0.00

Beta (Volatility)

0.47 (Low)

Price

$39.16

Volume

1,531

Open

$38.25

Previous Close

$38.18

Daily Range

$37.90 - $39.16

52-Week Range

$17.73 - $47.40

Estimated Earnings Date

Aug 17, 2026

BKYI News

featured-earnings-leadership-highlights.png

BIO-key Revenue Jumps 49 Percent in Q2

Motley Fool Markets TeamAug 13, 2025
Foolcom-Featured.png

BIO-key Revenue Jumps 49% in Q2

Motley Fool Markets TeamAug 13, 2025

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About BIO-key International

BIO-key helps companies and schools control access to digital systems. Its fingerprint and identity software lets users log in securely without passwords. These tools help protect sensitive data for businesses, governments, and universities.

Fingerprints, Passwords, and Portals: What BIO-key Sells

  • Identity Access Management (IAM) Platforms: PortalGuard and PortalGuard IDaaS control user access to apps and devices; 47% of Q2 2025 revenue.
  • Biometric Authentication Solutions: BIO-key VST and WEB-key use fingerprints for secure logins; target government and large organizations.
  • Biometric Hardware: SideSwipe, EcoID, and SidePass fingerprint scanners for businesses and consumers; 34% of Q2 2025 revenue.
  • Services: Maintenance, technical support, and custom integration; 19% of Q2 2025 revenue.

Growth Moves: BIO-key’s Expansion Playbook

  • Acquired Swivel Secure in 2022, expanding into Europe, Africa, and the Middle East.
  • Formed a channel alliance program with more than eighty-five participants to boost global sales reach.
  • Entered new markets in Africa, Asia, and South America between 2022 and 2025.
  • Invested in Boumarang (2025), a drone technology firm, for potential product integration.

Why BIO-key Stands Out in a Crowd

BIO-key’s platforms work with many fingerprint devices and support both cloud and on-site systems. Its products help organizations meet strict security rules without relying on phones or tokens. The company’s focus on regulated sectors and large ID projects sets it apart from many competitors.

Five Things You Need to Know

  • Q2 2025 revenue was $2M, up 48.7% from Q2 2024.
  • Hardware sales rose 581% year-over-year in Q2 2025.
  • Gross margin was 73% in Q2 2025, down from 77% in Q2 2024.
  • Net loss improved to $(1.17)M in Q2 2025, a 30% YoY improvement.
  • Cash at June 30, 2025 was $2.3M, but not enough for 12 months’ operations.

Bottom Line

BIO-key has evolved from a fingerprint tech firm to a global identity access provider. Its focus on flexible security tools and regulated markets shapes its current business model.

AI Generated • Apr 16, 2026

Industry

Software

Sector

Information Technology

Employees

42

CEO

Michael W. DePasquale

Website

www.bio-key.com

Headquarters

Holmdel, NJ 07733, US

BKYI Financials

Key Financial Metrics (TTM)

Gross Margin

77.84%

Operating Margin

-56.34%

Net Income Margin

-60.58%

Return on Equity

-57.42%

Return on Capital

-50.88%

Return on Assets

-37.62%

Earnings Yield

3.05%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$316.13MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

8.28M

Volume

1.53K

Avg. Volume

90.95K

Financials (TTM)

Gross Profit

$5.16M

Operating Income

-$3.74M

EBITDA

-$3.53M

Operating Cash Flow

-$4.19M

Capital Expenditure

-$7.44K

Free Cash Flow

-$4.19M

Cash & ST Invst.

$2.25M

Total Debt

$42.41K

BIO-key International Performance Analysis

BIO-key International annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 7,020,25837.3%
20232023-12-31USD 7,754,90510.5%
20242024-12-31USD 6,929,571-10.6%
20252025-12-31USD 5,937,555-14.3%
BIO-key International sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-305.6%
Q32025-09-30-8.7%
Q42025-12-31-19.9%
Q12026-03-3172.8%
BIO-key International annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -264.64126.1%
20232023-12-31USD -152.10-42.5%
20242024-12-31USD -20.88-86.3%
20252025-12-31USD -10.77-48.4%
BIO-key International sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-28.0%
Q32025-09-3027.4%
Q42025-12-31-78.1%
Q12026-03-3190.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$2.15M

+33.5%

Gross Profit

$1.77M

+33.3%

Gross Margin

82.46%

N/A

Market Cap

$316.13MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$7.53M

N/A

Employees

42

N/A

Net Income

-$165.04K

+77.6%

EBITDA

-$137.87K

+77.1%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$2.25M

-28.3%

Total Debt

$42.41K

-95.7%

Accounts Receivable

$1.57M

+86.5%

Inventory

$338.40K

-5.4%

Long Term Debt

$12.91K

-76.1%

Short Term Debt

$29.50K

-96.8%

Return on Assets

-37.62%

N/A

Return on Invested Capital

-49.78%

N/A

Free Cash Flow

-$358.00K

+57.4%

Operating Cash Flow

-$358.00K

+57.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
BAERBridger Aerospace Group Holdings, Inc. Common Stock
$1.84-2.13%
CIGLConcorde International Group Ltd.
$0.46-1.61%
SUNESUNation Energy Inc.
$2.40-7.69%
RVSNRail Vision Ltd.
$4.07+4.55%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$95.11-0.05%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.22-0.07%
ONDSOndas
$7.90-0.00%
CLFCleveland-Cliffs
$12.02+0.10%

Questions About BKYI

What is the current price of BIO-key International?

BIO-key International is trading at $39.16 per share.

What is the 52-week range for BIO-key International?

Over the past 52 weeks, BIO-key International has traded between $17.73 and $47.40.

How much debt does BIO-key International have?

As of the most recent reporting period, BIO-key International reported total debt of $706.70K.

How much cash does BIO-key International have on hand?

BIO-key International reported $2.25M in cash and cash equivalents in its most recent financial results.

What is BIO-key International’s dividend yield?

BIO-key International does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services